| Document |
Document Title |
|
WO/2013/191549A1 |
The invention relates to the field of carbohydrate chemistry. Provided is a process for the regioselective oxidation of a single secondary hydroxy function of a carbohydrate substrate comprising two or more secondary hydroxy functions, c...
|
|
WO/2013/190103A1 |
The invention relates to a sialic acid derivative of formula (I), wherein the symbols have the meanings specified in the description, which is suitable for linking to a cargo for regulating metabolic processes, immune reactions, immuniza...
|
|
WO/2013/188183A1 |
A rheology modifier which includes a mixture of short and long chain fatty acid esters is suitable for use in liquid surfactant-based compositions. A surfactant-based composition includes a surfactant, the rheology modifier, and water. T...
|
|
WO/2013/182206A1 |
The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically mod...
|
|
WO/2013/177985A1 |
A nitrogenous heterocyclic imide derivative having obvious insecticidal activity, and preparation method and uses thereof; the nitrogenous heterocyclic imide derivative and pharmaceutically acceptable salt thereof have been proved in pra...
|
|
WO/2013/170985A1 |
The present invention relates to paromamine-/neamine-based compounds according to formula I or II having selective antimicrobial activity directed at ribosomal 16S RNA and lacking ototoxicity. Furthermore, the invention is directed to th...
|
|
WO/2013/172640A1 |
The present invention relates to a pharmaceutical composition having a heat shock protein induction activity and comprising a compound isolated from Eucommia ulmoides. The compound isolated from Eucommia ulmoides according to the present...
|
|
WO/2013/167751A1 |
The invention relates to a method for enhancing the biosynthesis and/or secretion of sapogenins in the culture medium of plant and microbial cellcultures. Further, the present invention also relates to the identification of novel genes i...
|
|
WO/2013/162016A1 |
The purpose of the present invention is to provide a novel compound that is effective as an antitumor-active agent or a vaccine adjuvant, an intermediate useful in the synthesis of the compound, and a method for producing the same, as we...
|
|
WO/2013/156858A1 |
Advantageous compounds and methods for preventing and/or treating viral infections are provided.
|
|
WO/2013/152470A1 |
The present invention provides new ethyl salicylate glycosides compound, a synthetic method thereof, pharmaceutical compositions containing the ethyl salicylate glycosides compound, and applications of the ethyl salicylate glycosides com...
|
|
WO/2013/152848A1 |
The present invention relates to fucose- and mannose-derived glycomimetics and their general use in prophylaxis or treatment of Pseudomonas aeruginosa infections including respiratory tract infections, urinary tract infections, nosocomia...
|
|
WO/2013/149576A1 |
The present invention relates to a process of a chemically synthetic drug, and in particular, to a new intermediate of a heparin pentasaccharide and a preparation method thereof. The process has high reaction efficiency, and an easy reac...
|
|
WO/2013/146555A1 |
The purpose of the present invention is to provide a method for producing a steviol glycoside. The present invention provides a method for producing a steviol glycoside. The present invention provides: a transformant having a steviol gly...
|
|
WO/2013/143806A1 |
The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.
|
|
WO/2013/139344A1 |
3-O-Fucosyllactose is made by process which includes the hydrogenolysis of a new compound of the formula 1 wherein R1 and R2 are independently a group removable by hydrogenolysis, and R3 is a group removable by hydrogenolysis or H; or a ...
|
|
WO/2013/141350A1 |
The purpose of the present invention is to provide an oligosaccharide with high versatility that can produce a protected sulfate oligosaccharide that can become a manufacturing intermediate of polysulfated hyaluronic acid, and to provide...
|
|
WO/2013/142142A1 |
The present disclosure encompasses QS-21-based structurally-defined adjuvants to address the need for stronger, safer, and easier-to-access adjuvants. The new compositions can provide tools for addressing long-standing mechanistic questi...
|
|
WO/2013/137487A1 |
The purpose of the present invention is to provide: a steviol glycosyltransferase; and a method for producing a steviol glycoside using the enzyme. The present invention provides: a steviol glycosyltransferase; and a method for producing...
|
|
WO/2013/129667A1 |
A high-purity acid-form SL containing composition which is characterized by being substantially free from acetic acid. This high-purity acid-form SL containing composition can be prepared, for example, by a process which comprises: (i) a...
|
|
WO/2013/123896A1 |
Provided is a method for preparing 3-O-benzyl-1,2-O-isopropylidene-α-L-furan idose, which comprises: (1) protecting hydroxyl of 3-O-benzyl-1,2-O-isopropylidene-α-D-glucofuranose (III) by benzoyl and methylsulfonyl to obtain 6-O-benzoyl...
|
|
WO/2013/126730A1 |
Disclosed herein are novel oxetane derivatives of avicin D, including compounds of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising thes...
|
|
WO/2013/122112A1 |
Provided is a prodrug of a therapeutically active organic compound having: an amino group, a cyclic amino group or a hydroxyl group in the molecule; and a 2-nitro-1-imidazole propionic acid. In particular, provided is a prodrug in which ...
|
|
WO/2013/119985A1 |
Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral...
|
|
WO/2013/119857A1 |
Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating...
|
|
WO/2013/116480A1 |
Aminoglycoside antibiotics in the Kanamycin class having substitution at the 1 and 6" positions are disclosed. The compounds are useful for treating bacterial infections, particularly infections resistant to known antibiotics.
|
|
WO/2013/115157A1 |
Disclosed are: a pharmaceutical composition containing a compound represented by general formula (I) or a physiologically acceptable salt thereof as an active ingredient; and a method for treating cancer, characterized by administering a...
|
|
WO/2013/110704A1 |
The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for t...
|
|
WO/2013/108794A1 |
Provided is a polynucleotide that encodes a protein having the activity of transferring a sugar to a hydroxyl group at the 4'-position of a flavone. This polynucleotide is selected from the group consisting of: (a) a polynucleotide compr...
|
|
WO/2013/097942A1 |
Sialic acid derivatives of the formula (I), in which the symbols have the meanings specified in the description, are suitable as pharmaceuticals, in particular for diseases having a course influenced by siglec ligands.
|
|
WO/2013/096926A1 |
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagoni...
|
|
WO/2013/091660A1 |
A mixture of, preferably a mixture consisting essentially of, an lacto-N-tetraose (LNT) precursor (1) and an lacto-N-neotetraose (LNnT) precursor (2), (formula 1, 2), where R is a group removable by hydrogenolysis and R3 is either a grou...
|
|
WO/2013/093320A1 |
The invention relates to the use of 1-aryl-2-aryloxyethane compounds with formula I, wherein n and m are equal to 0 or 1, provided that n+m=1, R1 and R2 particularly representing hydrogen atoms, R3 and R4 particularly representing hydrog...
|
|
WO/2013/090296A1 |
Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes IL-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes IL-12 p40 subunit or a functional fragment thereof, a...
|
|
WO/2013/086131A1 |
Provided are compounds according to formula (la) or (lb) as described herein, that are capable of modulating the activity of influenza viruses (e.g., influenza A virus), for example, via interaction with the M2 transmembrane protein, and...
|
|
WO/2013/077433A1 |
The purpose of the present invention is to provide a keratoconjunctival protecting agent or a keratoconjunctival disorder inhibiting agent having an outstanding effect in suppressing keratoconjunctival disorders. This invention comprises...
|
|
WO/2013/073659A1 |
Provided is a method for producing a glycoside having a phenol as the aglycone thereof, which is a method that: does not require an expensive catalyst or enzyme; does not require following a complex synthesis pathway; is a method for dir...
|
|
WO/2013/073657A1 |
Provided is a method for directly producing an oligoglucoside from a saccharide chain including glucose as a constitutional unit thereof, by: reacting a saccharide chain including glucose as a constitutional unit thereof with a compound ...
|
|
WO/2013/072355A1 |
The present invention relates to new anti-infectious compounds consisting of (i) a polar head having from one to three mannose, dimannose or trimannose moieties, which is coupled through an appropriate linker to (ii) a single lipid chain...
|
|
WO/2013/071409A1 |
A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an interger between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16: l, C 18:0 or C18: l fa...
|
|
WO/2013/065383A1 |
A compound represented by structural formula (A) or a salt thereof. The compound or the salt thereof is produced suitably from a microorganism belonging to the genus Saccharothrix and can be used suitably as a prostaglandin production in...
|
|
WO/2013/059927A1 |
The present application relates to the compounds of formula I (I) as well as their use for inhibiting at least one of AKT-1, FAK and PKCα and in the treatment and/or prevention of metastatic diseases.
|
|
WO/2013/061816A1 |
The present description discloses a novel biologically active ingredient of manuka honey. Specifically, the present description discloses a compound represented by formula (AA). (In the formula, each of R1, R2 and R3 independently repres...
|
|
WO/2013/061802A1 |
The purpose of the present invention is to provide a method for producing a composition containing glyceryl glucoside, which does not undergo discoloration and is gentle to the skin. Provided is a method for producing a composition conta...
|
|
WO/2013/052012A1 |
The disclosure provides cationic peptidopolysaccharides of Formula I: which has a bacterial peptidoglycan-mimetic structure, and shows outstanding broad spectrum activities against clinically significant bacteria and fungi. The structura...
|
|
WO/2013/052615A1 |
A method for controlling pests by modifying derivatives of sophoroiipids (SL) and applying the modified sophorolipid derivatives (MSL) to the plant pathogen or to an environment in which the pathogens may occur or are located in an amoun...
|
|
WO/2013/050497A1 |
The present invention relates to a process of preparation of L-iduronic acid and derivatives comprising a decarboxylation/intramolecular cyclisation tandem reaction. The present invention also relates to the intermediates of the process,...
|
|
WO/2013/044928A1 |
The invention relates to a method for making precursors of HMO core structures comprising a step of reacting an N-acetyllactosamine or lacto-N-biose derivative donor with a lactose or N-acetyllactosamine derivative acceptor, wherein the ...
|
|
WO/2013/048227A1 |
The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener. The...
|
|
WO/2013/041732A1 |
The present invention relates to the total chemical synthesis of the monosaccharide 35# (R' = H), the disaccharide 36# (R' ≠H; R'' = H), the trisaccharide 37# (R' ≠H; R'' ≠H; R''' = H) and the tetrasaccharide 1#(R' ≠H; R'' â‰...
|
